减肥手术后肝脏体积的减少及其对肝功能测试和脂质谱的积极影响
Mauricio Sarmiento-Cobos1, Avraham Adelman1, Kyle Murchison1
1Department of General Surgery, Bariatric and Metabolic Institute, Cleveland Clinic Florida, Weston, Florida.
概括
腹腔外科手术 (BaS) 显著减少肝脏体积,并改善肥胖患者的肝功能和脂质概况. 这种减肥干预可以帮助预防脂肪肝疾病向纤维化进展.
科学领域:
- 代谢和腹部手术的代谢和腹部手术
- 肝病学 肝病学是一种肝病学.
- 肥胖医学 肥胖医学
背景情况:
- 肥胖是非酒精性脂肪性肝病 (NAFLD),肝脏内甘油三酸积累和肝纤维化的重要危险因素.
- 这些肝脏异常可以发展为严重的肝脏疾病,影响患者的健康结果.
研究的目的:
- 为了研究减肥手术 (BaS) 诱导的减肥对肝脏体积的影响.
- 在BaS之后评估肝功能测试和脂质概况的变化.
主要方法:
- 在2006年至2018年期间接受BaS治疗的73名患者的回顾性审查.
- 对腹部CT扫描进行分析,以检测手术前和后 (18个月) 肝体积变化.
- 收集和比较氨酸氨基转移酶 (ALT),酸氨基转移酶 (AST) 和BAS前后的脂质资料.
主要成果:
- 腹腔外科手术导致肝脏体积显著减少 (1870.73 mm3到1555.15 mm3,P = .004).
- 手术后,患者的肝功能得到改善,ALT水平降低 (36.9~23.8,P=0.024).
- 在脂质配置文件中观察到显著的改善,包括降低的甘油三 (135.62至97.50,P = .009) 和LDL胆固醇 (107.9至89.6,P = .048) 水平.
结论:
- 腹腔外科手术有效地减少肝脏体积,并改善肥胖患者的肝功能和脂质概况.
- 这些发现表明,BaS可能在缓解脂肪肝疾病的进展和潜在地预防纤维化方面发挥作用.
相关概念视频
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...